New Delhi: The shares of Biocon, PB Fintech and GMR Airports are expected to be in focus on May 27, 2025, Friday. Biocon will acquire debentures of Biocon Biologics from Goldman Sachs for USD 198.5 million. GMR Airports’ subsidiary completed 70 per cent stake purchase in group company. PB Fintech founders sold over 1 per cent stake for Rs 920 crore.
PB Fintech
The shares of PB Fintech are expected to be in news today after co-founders Yashish Dahiya and Alok Bansal offloaded a little over 1 per cent stake in the company for Rs 920 crore through open market transactions.
Dahiya, who serves as PB Fintech’s chief executive and Vice Chairman Bansal sold a total of 50.50 lakh shares in the company. PB Fintech is the parent of insurtech platform Policybazaar and fintech platform Paisabazar.
PB Fintech shares closed at Rs 1830 apiece on June 26, 2025.
GMR Airports
The acquisition of a 70 per cent stake in its associate company — ESR GMR Logistics Park Pvt Ltd by GMR Hyderabad International Airport Ltd has been, GMR Airports confirmed.
GMR Hyderabad Aerotropolis Ltd (GHAL), which is a wholly-owned subsidiary of GMR Hyderabad International Airport, has 30 per cent stake in ESR GMR Logistics Park Pvt Ltd (EGLPPL).
“… Upon fulfilment of conditions precedent, the process of transfer of share and exchange of consideration between the GHIAL and ESR Group has been concluded,” GMR Airports said in a regulatory filing on Thursday.
Biocon
Biocon Ltd board has given the green signal to the acquisition of optionally convertible debentures of its arm Biocon Biologics Ltd from Goldman Sachs for USD 198.5 million.
The board of directors of the biotechnology firm held a meeting on June 26, 2025, and gave its nod to the acquisition of optionally convertible debentures (OCDs) of Biocon Biologics Ltd, an unlisted subsidiary, from Goldman Sachs India Alternative Investment Trust AIF Scheme 2 and Goldman Sachs India AIF Scheme-1 (Goldman Sachs).
Biocon will “purchase 1,125 unlisted, unsecured, redeemable, optionally convertible debentures (OCDs) of Biocon Biologics of the face value of Rs 1 crore each for a consideration of rupee equivalent to USD 198.5 million, which may be varied depending on the date of purchase”, the company said in a regulatory filing.